Blonde L, et al. - Using the MarketScan claims database, authors comparatively analyzed the clinical and economic outcomes among patients with uncontrolled type 2 diabetes (T2D) initiating 2 oral antidiabetes drugs (OADs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or basal insulin. Several patients did not achieve HbA1c < 7.0% regardless of robust HbA1c lowering following treatment initiation. A connection was brought to light between basal insulin, generally prescribed for patients with high baseline HbA1c, with a large reduction in HbA1c and with higher costs.